Filing Details
- Accession Number:
- 0000899243-19-027115
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-11-12 16:15:33
- Reporting Period:
- 2019-11-12
- Accepted Time:
- 2019-11-12 16:15:33
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1563577 | Galera Therapeutics Inc. | GRTX | Pharmaceutical Preparations (2834) | V8 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1114448 | Ag Novartis | Lichtstrasse 35, Ch-4056 Basel V8 CH-4056 | No | No | Yes | No | |
| 1297709 | Ltd Bioventures Novartis | C/O Novartis Venture Fund Forum 1 - 1.32, Lichtstrasse 35, Ch-4056 Basel V8 CH-4056 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-11-12 | 3,293,067 | $0.00 | 3,293,067 | No | 4 | C | Indirect | See footnote |
| Common Stock | Acquisiton | 2019-11-12 | 250,000 | $12.00 | 3,543,067 | No | 4 | P | Indirect | See footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See footnote |
| No | 4 | P | Indirect | See footnote |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Preferred Stock | Disposition | 2019-11-12 | 9,000,000 | $0.00 | 1,779,864 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2019-11-12 | 7,200,000 | $0.00 | 1,423,891 | $0.00 |
| Common Stock | Series C Preferred Stock | Disposition | 2019-11-12 | 451,609 | $0.00 | 89,311 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.
- Novartis Bioventures Ltd. Is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities.
Billionaire Hedge Funds
